Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2003

View Archived Issues

Potential cardiovascular benefits induced by rosiglitazone in diabetes and insulin resistance

Synthetic retinal peptide improves functional activity in diabetic retinopathy

Improved pharmacokinetic and pharmacodynamic profile found for insulin detemir in type 1 diabetes

Pioglitazone improves glucose tolerance and microvascular function in type 2 diabetes

Severe oral mucositis in cancer patients improved by rHuKGF

Remune enters treatment interruption study in HIV-1-infected patients

Phase III Theratope vaccine trial fails to meet primary endpoints

Calpain inhibitors with improved pharmacokinetics and neuroprotective efficacy

New antibacterial tylosin analogues covered by Enanta patent

Gabusectin, a novel antibiotic prepared and tested by Aventis researchers

Adenosine A2A receptor ligands and their use reported by Roche

Novel CRF antagonists for use in anxiety, depression and IBS

Sanofi-Synthelabo claims novel TNF-alpha production inhibitors in recent patent

Lilly reports new series of PPARalpha agonists

Beta-secretase inhibitors identified by Elan and Pharmacia (Pfizer) team

Boston Life Sciences to pursue SPA for phase III study of Altropane

Novuspharma to merge with Cell Therapeutics

Enzon acquires North American license to ATG-Fresenius S

Metvix label extension recommended in Australia

Second phase IIa study for TA-CD in cocaine dependence reports findings

Enrollment completed in phase II/III European trial of Trabio

CARDS Lipitor trial stopped two years early because of significant atorvastatin benefit

Forsteo approved in E.U. for treatment of osteoporosis in postmenopausal women

FDA approves FluMist as first intranasal influenza vaccine

Specific human mast cell tryptase inhibitor blocks collagen production in human lung fibroblasts

New nonestrogenic inhibitors of human steroid sulfatase synthesized at Theramex

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...